|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021756,
umls-concept:C0030705,
umls-concept:C0243009,
umls-concept:C0392747,
umls-concept:C0439231,
umls-concept:C0439378,
umls-concept:C1516050,
umls-concept:C1522577,
umls-concept:C1552601,
umls-concept:C1561565,
umls-concept:C2698872
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2007-3-13
|
|
pubmed:abstractText |
ESPRIT is a randomized trial comparing the clinical impact of interleukin (IL)-2 plus antiretrovirals vs antiretrovirals alone. Identification of factors that influence the relationship between IL-2 and CD4 count recovery will enable better personalization of treatment with IL-2 in HIV-1-positive individuals. The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1464-2662
|
|
pubmed:author |
pubmed-author:AntunesFranciscoF,
pubmed-author:DaveyRickR,
pubmed-author:ESPRIT Research Group,
pubmed-author:GazzardBrianB,
pubmed-author:GuoY EYE,
pubmed-author:KlimasNancyN,
pubmed-author:LabriolaAnnA,
pubmed-author:LossoMarceloM,
pubmed-author:LundgrenJens DJD,
pubmed-author:NeatonJames DJD,
pubmed-author:PhillipsAndrew NAN,
pubmed-author:RuxrungthamKiatK,
pubmed-author:StaszewskiSchlomoS,
pubmed-author:WeissLaurenceL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
112-23
|
|
pubmed:meshHeading |
pubmed-meshheading:17352768-Adult,
pubmed-meshheading:17352768-CD4 Lymphocyte Count,
pubmed-meshheading:17352768-Drug Administration Schedule,
pubmed-meshheading:17352768-Drug Therapy, Combination,
pubmed-meshheading:17352768-Female,
pubmed-meshheading:17352768-HIV Infections,
pubmed-meshheading:17352768-HIV Protease Inhibitors,
pubmed-meshheading:17352768-HIV-1,
pubmed-meshheading:17352768-Humans,
pubmed-meshheading:17352768-Interleukin-2,
pubmed-meshheading:17352768-Male,
pubmed-meshheading:17352768-Patient Compliance,
pubmed-meshheading:17352768-RNA, Viral,
pubmed-meshheading:17352768-Recombinant Proteins,
pubmed-meshheading:17352768-Reverse Transcriptase Inhibitors
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.
|
|
pubmed:affiliation |
Hvidovre University Hospital, DK-2650 Hvidovre, Denmark. z.fox@pcps.ucl.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
